WallStreetZenWallStreetZen

NASDAQ: ADMA
Adma Biologics Inc Stock

$10.63-0.15 (-1.39%)
Updated Jun 14, 2024
ADMA Price
$10.63
Fair Value Price
N/A
Market Cap
$2.46B
52 Week Low
$3.06
52 Week High
$10.86
P/E
-531.5x
P/B
16.03x
P/S
5.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$283.18M
Earnings
-$3.64M
Gross Margin
39.4%
Operating Margin
6.93%
Profit Margin
-1.3%
Debt to Equity
1.28
Operating Cash Flow
$21M
Beta
0.87
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ADMA Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ADMA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADMA is poor value based on its book value relative to its share price (16.03x), compared to the US Biotechnology industry average (6.25x)
P/B vs Industry Valuation
ADMA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ADMA due diligence checks available for Premium users.

Be the first to know about important ADMA news, forecast changes, insider trades & much more!

ADMA News

Valuation

ADMA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-531.5x
Industry
-10.23x
Market
30.51x

ADMA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
16.03x
Industry
6.25x
ADMA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ADMA's financial health

Profit margin

Revenue
$81.9M
Net Income
$17.8M
Profit Margin
21.7%
ADMA's Earnings (EBIT) of $19.63M... subscribe to Premium to read more.
Interest Coverage Financials
ADMA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$350.9M
Liabilities
$197.2M
Debt to equity
1.28
ADMA's short-term assets ($276.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADMA's short-term assets ($276.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADMA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.2M
Investing
-$2.4M
Financing
-$1.4M
ADMA's operating cash flow ($21.30M)... subscribe to Premium to read more.
Debt Coverage Financials

ADMA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ADMA$2.46B-1.39%-531.50x16.03x
ACAD$2.46B-1.19%-1,491.00x5.31x
NTLA$2.43B-3.12%-4.69x2.34x
AGIO$2.50B-5.69%-6.98x3.37x
APGE$2.40B-4.59%-7.84x3.00x

Adma Biologics Stock FAQ

What is Adma Biologics's quote symbol?

(NASDAQ: ADMA) Adma Biologics trades on the NASDAQ under the ticker symbol ADMA. Adma Biologics stock quotes can also be displayed as NASDAQ: ADMA.

If you're new to stock investing, here's how to buy Adma Biologics stock.

What is the 52 week high and low for Adma Biologics (NASDAQ: ADMA)?

(NASDAQ: ADMA) Adma Biologics's 52-week high was $10.86, and its 52-week low was $3.06. It is currently -2.07% from its 52-week high and 247.39% from its 52-week low.

How much is Adma Biologics stock worth today?

(NASDAQ: ADMA) Adma Biologics currently has 231,809,197 outstanding shares. With Adma Biologics stock trading at $10.63 per share, the total value of Adma Biologics stock (market capitalization) is $2.46B.

Adma Biologics stock was originally listed at a price of $8.55 in Oct 17, 2013. If you had invested in Adma Biologics stock at $8.55, your return over the last 10 years would have been 24.33%, for an annualized return of 2.2% (not including any dividends or dividend reinvestments).

How much is Adma Biologics's stock price per share?

(NASDAQ: ADMA) Adma Biologics stock price per share is $10.63 today (as of Jun 14, 2024).

What is Adma Biologics's Market Cap?

(NASDAQ: ADMA) Adma Biologics's market cap is $2.46B, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Adma Biologics's market cap is calculated by multiplying ADMA's current stock price of $10.63 by ADMA's total outstanding shares of 231,809,197.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.